AstraZeneca says COVID-19 shot was equally effective to mRNA vaccines in review
Roland Magnusson/iStock Editorial via Getty Images


Citing a review of 79 real-world studies, AstraZeneca (NASDAQ:AZN) announced Wednesday that its vector-based COVID-19 vaccine Vaxzevria was as effective as currently available messenger RNA vaccines from Pfizer (PFE)/BioNTech (BNTX) and Moderna (MRNA).

The infectious disease experts from Asia conducted the review based on the VIEW-hub database on vaccine use and impact, compiled by Johns Hopkins Bloomberg School of Public Health and the International Vaccine Access Center.
According to data, Vaxzevria and the BNT162b2 from Pfizer (PFE)/BioNTech (BNTX) and mRNA-1273 from Moderna (MRNA) were found to offer an equivalent level of protection in terms of hospitalizations (91-93%) and death (91-93%) regardless of age.
While the data related to Delta and earlier variants of COVID-19, Astra (AZN) said that new data from the UK Health Security Agency and Brazil on third vaccine dose demonstrated similar findings against severe outcomes of the disease due to Omicron.
Reporting $1.5B in sales from Vaxzevria for 1Q 2022, Astra (AZN) projected its revenue for the vaccine to drop in 2022